The market's newfound volatility and declines are giving investors one thing that should not be overlooked. And that is, the market is forcing many new and promising IPO stocks into corrections and base building patterns.
If you follow Investor's Business Daily (IBD), the seesaw reaction in its market outlook this year was a indicator to an aging bull run. Caution has been rewarded. But even in markets like these, new companies emerge, and one should not lose focus on what looks promising.
Recently, IBD hosted an hour-long webinar on IPO investing. This video can be found on its website. An abbreviated version of it was posted a year ago, and we've posted it here:
Yesterday, we posted a chart from TradingView on a stock that we highlighted on Seeking Alpha last month, Rapid 7. The stock has been in a two-month IPO base, which we interpret to be a double-bottom. The buy point is $25.48. Monday's trade took RPD to the brink of this price on heavy volume. As of this writing, the stock has backed off amid the broad market selloff. We intend to buy this stock at this buy point.
Tuesday, September 22, 2015
Monday, September 21, 2015
Wednesday, September 2, 2015
IPO Class of 2015: A Top 25 Ranking
Today the markets staged a big advance, led by the Nasdaq's 2.46% rally. Nevertheless, we remain in a market correction. The IPO market has quieted down in the aftermath, with nothing expected to price in the next few weeks. In the meantime, we screened the IPO Class of 2015, and ranked them by their performance. Here are the Top 25, as of today's close:
1. Tantech Holdings (TANH) up 623% since March 24 IPO date
2. The Global Blood (GBT) up 160% since August 11 IPO date
3. Seres Therapeutics (MCRB) up 133% since June 25 IPO date
4. Inotek Pharmaceuticals (ITEK) up 132% since Feb 18 IPO
5. Shake Shack (SHAK) up 131% since Jan 29 IPO
6. Zynerba Pharma (ZYNE) up 115% since Aug 4 IPO
7. Spark Therapeutics (ONCE) up 89% since Jan 30 IPO
8. Kempharm Inc (KMPH) up 82% since Apr 15 IPO
9. Pronai Therapeutic (DNAI) up 79% since July 15 IPO
10. Neos Therapeuritc (NEOS) up 77% since July 23 IPO
11. Chiasma Inc (CHMA) up 77% since July 15 IPO
12. Fitbit Inc (FIT) up since June 17 IPO
13. Glaukos Corp (GKOS) up 66% since June 24 IPO
14. Blueprint Medical (BPMC) up 58% since April 29 IPO
15. Kearny Financial (KRNY) up 57% since May 14 IPO
16. Wingstop (WING) up 44% since June 11 IPO
17. Solaredge Technology (SEDG) up 41% since March 26 IPO
18. Aimmune Therapeutic (AIMT) up 39% since Aug 5 IPO
19. Black Knight (BKFS) up 37% since May 19 IPO
20. Press Ganey (PGND) up 33% since May 20 IPO
21. Appfolio (APPF) up 31% since June 25 IPO
22. Summit Materials (SUM) up 30% since March 11 IPO
23. Rapid 7 Inc (RPD) up 30% since July 16 IPO
24. Entellus Medical (ENTL) up 29% since Jan 28 IPO
25. Collegium Pharma (COLL) up 26% since May 6 IPO
Once again we point out the overwhelming presence of healthcare companies on this list. Biotechs and pharmaceuticals have dominated the IPO market of the recent bull cycle. Of particular interest is the performance of GBT, ZYNE, DNAI and NEOS, which have all managed huge returns in the past month in spite of the overall market correction.
We have provided links to the two companies we've recently published research on Seeking Alpha, AIMT and RPD.
Should the market correction resolve itself in the coming weeks, we will post any actions we take. To date, our portfolio is in all cash. Readers of IBD will note the occurrence of a follow-through day to change the market from correction to a bull uptrend.
1. Tantech Holdings (TANH) up 623% since March 24 IPO date
2. The Global Blood (GBT) up 160% since August 11 IPO date
3. Seres Therapeutics (MCRB) up 133% since June 25 IPO date
4. Inotek Pharmaceuticals (ITEK) up 132% since Feb 18 IPO
5. Shake Shack (SHAK) up 131% since Jan 29 IPO
6. Zynerba Pharma (ZYNE) up 115% since Aug 4 IPO
7. Spark Therapeutics (ONCE) up 89% since Jan 30 IPO
8. Kempharm Inc (KMPH) up 82% since Apr 15 IPO
9. Pronai Therapeutic (DNAI) up 79% since July 15 IPO
10. Neos Therapeuritc (NEOS) up 77% since July 23 IPO
11. Chiasma Inc (CHMA) up 77% since July 15 IPO
12. Fitbit Inc (FIT) up since June 17 IPO
13. Glaukos Corp (GKOS) up 66% since June 24 IPO
14. Blueprint Medical (BPMC) up 58% since April 29 IPO
15. Kearny Financial (KRNY) up 57% since May 14 IPO
16. Wingstop (WING) up 44% since June 11 IPO
17. Solaredge Technology (SEDG) up 41% since March 26 IPO
18. Aimmune Therapeutic (AIMT) up 39% since Aug 5 IPO
19. Black Knight (BKFS) up 37% since May 19 IPO
20. Press Ganey (PGND) up 33% since May 20 IPO
21. Appfolio (APPF) up 31% since June 25 IPO
22. Summit Materials (SUM) up 30% since March 11 IPO
23. Rapid 7 Inc (RPD) up 30% since July 16 IPO
24. Entellus Medical (ENTL) up 29% since Jan 28 IPO
25. Collegium Pharma (COLL) up 26% since May 6 IPO
Once again we point out the overwhelming presence of healthcare companies on this list. Biotechs and pharmaceuticals have dominated the IPO market of the recent bull cycle. Of particular interest is the performance of GBT, ZYNE, DNAI and NEOS, which have all managed huge returns in the past month in spite of the overall market correction.
We have provided links to the two companies we've recently published research on Seeking Alpha, AIMT and RPD.
Should the market correction resolve itself in the coming weeks, we will post any actions we take. To date, our portfolio is in all cash. Readers of IBD will note the occurrence of a follow-through day to change the market from correction to a bull uptrend.
Subscribe to:
Posts (Atom)